Australia In-Vitro Diagnostics Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia in-vitro diagnostics market is a laboratory-led business in which large pathology networks buy platforms and reagents under multi-year supply contracts. Self-testing and point-of-care formats are small but growing, as pharmacies, community clinics and consumers gain access to regulated rapid tests.

Three forces shape the outlook: Medicare-funded test volumes that grow slowly and are tightly managed; regulatory change at the Therapeutic Goods Administration covering classification, companion diagnostics and software; and a move towards molecular, oncology and decentralised testing.

In May 2025, the Therapeutic Goods Administration issued companion diagnostics guidance and a diagnostic list. In November 2025, Medicare began funding DPYD gene testing, and in August 2026 the three listed pathology groups reported results showing price and mix outpacing volume.

Key Market Trends and Insights

• Soft volumes: Healius reported on 19 August 2026 that pathology volumes fell 1.3% in the year to 30 June 2026, while revenue rose 1.8% to AUD 1.33 billion on pricing and mix.
• Near-universal bulk billing: The Medical Republic reported in July 2026 that out-of-hospital pathology bulk billing reached 99.7% in the March 2026 quarter, leaving little room for patient-funded price rises.
• Precision testing funded: Medicare listed DPYD gene testing on 1 November 2025 and a cholangiocarcinoma DNA and RNA fusion panel on 1 July 2026, widening reimbursed molecular menus.
• Pharmacy self-testing: Atomo Diagnostics reported in July 2026 that the pharmacy network stocking its HIV self-test grew from 147 to 196 sites in Australia.

Australia In-Vitro Diagnostics Market Size and Forecast

The market is shifting from a volume story to a value story, as menu expansion, automation and higher-value assays lift revenue per sample while Medicare-capped test counts stay broadly flat. Immunoassay remains the largest technology, with molecular diagnostics advancing fastest, and cardiometabolic testing leads applications while oncology grows quickest. Private pathology laboratories buy the most, yet home and pharmacy self-testing expands at the fastest pace. New South Wales is the largest region and Queensland grows quickest. Regulatory reform, laboratory consolidation and decentralised testing underpin a steady, mid-single-digit outlook.

Key Takeaways: Australia In-Vitro Diagnostics Market

Value Growth Outpaces Test Volume

Revenue is on course to expand by about 69% across the decade, from AUD 2.05 billion in 2025 to AUD 3.47 billion in 2035 at a 5.4% CAGR. Menu expansion, automation and richer test mix lift value faster than Medicare-capped volumes.

Molecular and Home Testing Lead

Molecular Diagnostics grows at an estimated 7.8% CAGR and Home and Pharmacy Self-Testing at an estimated 8.6% CAGR through 2035. Oncology advances at 7.2% as tumour-profiling items enter the Medicare schedule.

Regulation and Funding Shape Competition

Reclassification at the Therapeutic Goods Administration and tight Medicare pricing favour suppliers with compliant portfolios and scale inside laboratory networks, while smaller developers compete through niche assays and export markets.

• 25 submissions informed the TGA classification review, reported in July 2026
• Bulk billing of 99.7% in the March 2026 quarter limits pricing power
• Healius pathology volumes fell 1.3% in the year to 30 June 2026

Australia In-Vitro Diagnostics Market Report Summary

Key Insight

Medicare-funded testing, an ageing population and growing precision-medicine demand support steady value growth, while tight pricing caps volume. Immunoassay leads, and molecular and self-testing formats grow fastest.

Key Trends in the Australia In-Vitro Diagnostics Market

The Australia in-vitro diagnostics market is being reshaped by flat laboratory volumes, scrutiny of patient charges, new reimbursed precision tests and the spread of rapid testing beyond the laboratory.

August 2026 - Pathology Leaders Report Price and Mix Over Volume

• Healius reported on 19 August 2026 that pathology revenue rose 1.8% to AUD 1.33 billion while volumes fell 1.3%, with a goodwill impairment of AUD 332.0 million.
• Australian Clinical Labs reported on 17 August 2026 revenue of AUD 735.8 million, down 0.7%, citing a low-growth market and Medicare fee changes.
• Sonic Healthcare lodged group revenue of AUD 10.87 billion on 20 August 2026, up 13%, including organic growth of 5%.

July 2026 - Pathology Gap Fees Draw Ministerial Attention

• On 8 July 2026 Minister Mark Butler said 'something's gone wrong' on pathology charges, as The Medical Republic reported on 9 July 2026.
• Out-of-hospital pathology bulk billing stood at 99.7% in the March 2026 quarter, according to the Medicare data the article cited.
• Butler suggested incomplete referral forms may stop laboratories applying the correct rebate, an explanation the article could not confirm fully.

June 2026 - Rapid Multiplex Sexual Health Testing Gains Attention

• On 4 June 2026 HIV Australia featured a point-of-care test that can diagnose syphilis, herpes simplex virus, chlamydia and gonorrhoea in under an hour.
• Dr Shivani Pasricha of the Peter Doherty Institute described its value for rural, remote and underserved communities.
• Faster results support treatment at the same visit, which is the core case for decentralised testing in clinics and community services.

November 2025 - Medicare Adds Precision Testing Items

• From 1 November 2025 Medicare funds DPYD genotyping, item 73322, to predict fluoropyrimidine toxicity, once per lifetime on specialist request.
• Faecal calprotectin, item 66525, became rebatable on the same date for monitoring diagnosed inflammatory bowel disease.
• On 1 July 2026 a cholangiocarcinoma DNA and RNA fusion panel, item 73329, followed, covering IDH1 variant and FGFR2 fusion status.

Key Insight

Flat laboratory volumes and scrutiny of patient charges pull against new reimbursed precision tests and decentralised formats. Suppliers with automation and molecular menus gain as networks chase efficiency.

Recent Market Developments in the Australia In-Vitro Diagnostics Market

Recent developments, presented from the most recent, show the Australia in-vitro diagnostics market moving through local developer growth, export wins and a steady stream of regulatory reform.

August 2026 - Genetic Signatures Signs a Danish Hospital Supply Deal

• On 25 August 2026 Genetic Signatures reported revenue of AUD 14.8 million, down 7%, with Australia contributing AUD 13.2 million.
• It cited intense price competition and a delayed, subdued respiratory season, and expects restructuring to save about AUD 5 million a year.
• Hvidovre Hospital in Denmark began commercial testing in August 2026 under a ten-year supply agreement won through tender.

July 2026 - Atomo Diagnostics Lifts Revenue on HIV Self-Test Sales

• On 23 July 2026 Atomo Diagnostics reported annual revenue of AUD 5.3 million, up 40%, with fourth-quarter HIV sales of about AUD 1.6 million.
• Its Australian pharmacy network grew from 147 to 196 locations, and 70 pharmacies were activated in New Zealand.
• Syphilis clinical trials are planned for mid-way through the next financial year, with a liver function test in business planning.

July 2026 - TGA Reports Stakeholder Views on IVD Reform

• In a July 2026 document the TGA reported 25 submissions on in-vitro diagnostic reforms and support for revised classification rules.
• Stakeholders did not back a six-month transition for classification changes, and targeted consultation on transitional arrangements is a next step.
• In December 2025 the TGA added a United Kingdom approved body to its comparable overseas regulator pathway, and updated software guidance followed in February 2026.

May 2025 - TGA Publishes Companion Diagnostic Guidance and a List

• In May 2025 the TGA released companion diagnostics guidance and introduced a list of companion diagnostics.
• Input on companion diagnostic requirements for in-house tests fed into the consultation on updating the in-house IVD standard.
• In August 2025 the TGA began a review of software-based medical devices, including those using artificial intelligence.

Key Insight

Recent events show local developers growing through pharmacy and export channels, while regulators revise classification and widen reliance on overseas approvals, raising compliance workloads for every supplier.

Australia In-Vitro Diagnostics Industry Segmentation

The Expert Market Research’s report on the Australia In-Vitro Diagnostics Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Technology

• Immunoassay
• Clinical Chemistry
• Molecular Diagnostics
• Haematology and Coagulation
• Others

Immunoassay leads revenue through hormone, cardiac and tumour-marker panels, and Roche announced CE marking of its Elecsys pTau217 blood test for Alzheimer's pathology in May 2026. Clinical Chemistry covers renal, liver and lipid panels that sustain steady volume. Molecular Diagnostics grows fastest at an estimated 7.8% CAGR, helped by Medicare's DPYD gene test from November 2025 and a cholangiocarcinoma panel from July 2026. Haematology and Coagulation tracks routine blood-count demand. Others covers microbiology culture, urinalysis and blood gas testing.

Market Breakup by Application

• Cardiometabolic Disorders
• Infectious Diseases
• Oncology
• Autoimmune and Allergy
• Others

Cardiometabolic Disorders lead revenue through lipid, glycated haemoglobin and kidney panels ordered in primary care. Infectious Diseases follow, with Genetic Signatures citing a subdued respiratory season in August 2026 and rapid sexual health testing featured in June 2026. Oncology grows fastest at an estimated 7.2% CAGR as tumour-profiling items such as the cholangiocarcinoma panel begin in July 2026. Autoimmune and Allergy relies on specialist immunoassay panels. Others covers fertility, prenatal, toxicology and nutritional testing, where Medicare restricted vitamin B12 testing to once every 11 months from July 2025.

Market Breakup by End User

• Private Pathology Laboratories
• Hospital Laboratories
• Point-of-Care and Primary Care Clinics
• Home and Pharmacy Self-Testing
• Others

Private Pathology Laboratories lead, with Sonic Healthcare reporting group revenue of AUD 10.87 billion in August 2026 and Australian Clinical Labs running over 40 accredited laboratories. Hospital Laboratories buy through public tenders for inpatient and emergency work. Point-of-Care and Primary Care Clinics benefit from same-visit results in remote and community settings. Home and Pharmacy Self-Testing grows fastest at an estimated 8.6% CAGR, as Atomo Diagnostics grew its pharmacy network from 147 to 196 sites by July 2026.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Others

New South Wales dominates through the largest population and the Sydney headquarters of Sonic Healthcare and Healius, growing at an estimated 5.1% CAGR through 2035. Victoria follows at 5.2%, anchored by Australian Clinical Labs in Clayton. Queensland is the fastest-growing region at an estimated 5.9%, helped by population inflow and Sonic Healthcare's Brisbane hub laboratory, sold and leased back in the year to June 2026. Western Australia grows at 5.7% and South Australia at 5.0%. Others covers Tasmania, the ACT and the Northern Territory at 5.3%.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia In-Vitro Diagnostics Market

Competition spans global platform manufacturers, listed pathology networks and Australian test developers. Barriers include regulatory approval, multi-year laboratory supply contracts, instrument installed bases and Medicare-driven price pressure.

Sonic Healthcare

Sonic Healthcare, headquartered in Sydney, is one of Australia's largest pathology providers, with laboratories across Australia, Europe and North America. On 20 August 2026 it reported group revenue of AUD 10.87 billion, up 13%, and underlying EBITDA of AUD 1,933 million, guiding to AUD 1.95 billion to AUD 2.03 billion for the next year. It also completed a sale and leaseback of its Brisbane hub laboratory.

Healius

Healius, headquartered in Sydney, operates Australian pathology networks supplying community and hospital testing. On 19 August 2026 it reported pathology revenue up 1.8% to AUD 1.33 billion, pathology EBIT of AUD 23.8 million, a goodwill impairment of AUD 332.0 million and net debt of AUD 32.8 million. It is exploring a sale of Agilex Biolabs and delayed its margin target to about December 2028.

Australian Clinical Labs

Australian Clinical Labs, headquartered in Clayton, Victoria, operates over 40 accredited laboratories, over 1,270 collection centres and 28 specialist skin cancer clinics. On 17 August 2026 it reported revenue of AUD 735.8 million and underlying EBIT of AUD 69.2 million, and guided to revenue of AUD 745 million to AUD 765 million. Greg Horan became Group CEO on 31 August 2026.

Genetic Signatures

Genetic Signatures, a Sydney-based ASX-listed molecular diagnostics company, sells EasyScreen multiplex assays in more than 30 countries, with Australia its principal market. It reported on 25 August 2026 revenue of AUD 14.8 million, of which Australia contributed AUD 13.2 million. In August 2026 it began commercial testing under a ten-year supply agreement with Hvidovre Hospital in Denmark.

Other players operating in the Australia in-vitro diagnostics market include Roche Diagnostics, Abbott Diagnostics, Siemens Healthineers, bioMérieux, and Atomo Diagnostics, alongside regional distributors, reagent suppliers, point-of-care device makers and public pathology services supplying tests across Australia.

Key Insight

Scale in laboratory networks, reagent supply contracts and regulatory compliance decide competitiveness. Global manufacturers supply platforms, while listed local operators compete on turnaround, coverage and cost efficiency.